INSIDE THIS ISSUE

- Doctors Drive Treatment Choice in Men Diagnosed with Prostate Cancer
- ADT Heads List of Therapies in New Prostate Cancer Guideline
- Results of the COMET-1 Phase 3 Trial of Cabozantinib in Men with mCRPC
- Observer Reproducibility in Interpreting PET/CT Examinations in Men with BCR
- Number of Cores at 1st Biopsy & the Need for Confirmatory Biopsy in Active Surveillance
- Doc Moyad’s “No Bogus Science” Column – “Which Diet Is the Best for You?”
- A Treatment Option for Advanced Prostate Cancer that Has Spread to the Bones
- Variation in Treatment vs. Life Expectancy in Men with Early-Stage Prostate Cancer
- Doctor Chodak’s Bottom Line
- FDA Approves New Use of XTANDI® for mCRPC Patients Prior to Chemotherapy

DOCS DRIVE TREATMENT CHOICE IN PROSTATE CANCER

Physicians who diagnosed low-risk prostate cancer had more influence over the decision to enter active surveillance than did the disease characteristics, a review of 12,000 cases showed. Overall, about 20% of the men chose active surveillance as the initial approach to management. Rates of active surveillance among the diagnosing urologists varied from 4.5% to 64% of patients, according to Karen E. Hoffman, MD, MPH, of MD Anderson Cancer Center in Houston, and colleagues.

Analysis of factors that influenced treatment decision showed that the diagnosing physician had more than twice the impact on the choice of upfront therapy as compared with disease characteristics, as reported online in JAMA Internal Medicine.

“Primary care physicians who refer patients to urologists for prostate biopsy may assume that patients will receive similar management recommendations, regardless of the urologist they see,” the authors said. “We sought to determine whether this is indeed the case.”

They queried the Surveillance, Epidemiology and End Results database for men, ages 66 and older, with newly diagnosed low-risk prostate cancer during 2006 through 2009. Using Medicare-linked claims data, the authors obtained information on the diagnosing urologist, consulting radiation oncologist, cancer-directed therapy, and comorbidities.

(Continued on page 6)

ADT HEADS LIST OF THERAPIES IN NEW PROSTATE CANCER GUIDELINE

Indefinite continuation of androgen deprivation therapy (ADT) remains the cornerstone of systemic treatment for metastatic castration-resistant prostate cancer (mCRPC), augmented by new agents, according to a joint guideline from US and Canadian oncology groups.

In addition to ADT (medical or surgical), clinicians should offer men with mCRPC abiraterone (Zytiga®) plus prednisone, enzalutamide (Xtandi®), and radium-223 (Xofigo®), all of which have favorable benefit-harm profiles, the guideline indicated. Men also may be offered docetaxel plus prednisone, but should be thoroughly informed of potential toxicity.

Other systemic agents have niche roles in the treatment of mCRPC, as recommended by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO). The guideline was published online in the Journal of Clinical Oncology and is available on the ASCO website [www.asco.org].

“We have seen unprecedented progress against advanced prostate cancer recently, with six new treatments approved in the last couple of years,” guideline panel co-chair Ethan Basch, MD, of the University of North Carolina at Chapel Hill, stated. “There are a lot of nuances about treatment selection in terms of disease stage and what prior therapies the patient received. We hope this guideline will help doctors and patients make informed treatment decisions.”

(Continued on page 5)

EXELIXIS ANNOUNCES RESULTS FROM THE COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer

Exelixis, Inc. announced top-line results from the final analysis of COMET-1, the phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide. The trial did not meet its primary endpoint of demonstrating a statistically significant increase in overall survival (OS) for patients treated with cabozantinib as compared to prednisone. The median OS for the cabozantinib arm of the trial was 11.0 months versus 9.8 months for the prednisone arm (hazard ratio 0.90; 95% confidence interval [CI] 0.76–1.06; p = 0.212).

Cabozantinib inhibits the activity of tyrosine kinases including MET, VEGFRs and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.

The COMET-1 results are the subject of ongoing analyses. Exelixis will submit additional data, including secondary and exploratory endpoints, for presentation at a future medical conference. Besides OS, the exploratory endpoint of progression-free survival (PFS) as assessed by
STUDY OF INTER- AND INTRA-OBSERVER REPRODUCIBILITY IN THE INTERPRETATION OF (18)F CHOLINE PET/CT EXAMINATIONS IN PATIENTS SUFFERING FROM BIOCHEMICALLY RECURRENT PROSTATE CANCER FOLLOWING CURATIVE TREATMENT

Pegard C, Gallazzini-Crépin C, Giai J, et al

EJNMMI Res 4: 25, 2014

Objective: To assess whether the number of cores at first prostate biopsy affects pathologic findings at radical prostatectomy (RP) in potential candidates for active surveillance (AS).

Material and Methods: Two hundred seventy-five patients fulfilling Prostate Cancer Research International: Active Surveillance criteria (prostate-specific antigen level ≤ 10 ng/mL, prostate-specific antigen density <0.2 ng/mL/cm³, number of positive cores ≤2, T1c-T2 clinical stage, Gleason score [GS] ≤6) underwent RP between 2005 and 2013 at a single institution. Patients were stratified into three groups according to different biopsy schemes (≤12 vs 13-18 vs ≥19 cores). Rates of pathologically confirmed insignificant prostate cancer (pIPCa; defined as RP GS ≤6, tumor volume ≤0.5 mL, and organ-confined disease) and unfavorable disease (UD, defined as non-organ-confined disease and/or pathologic GS ≥7) at RP were stratified according to the biopsy schemes. Logistic regression analyses tested the effect of preoperative variables in predicting pIPCa and UD at RP.

Results: Of all, 23.3% and 33.4% patients harbored pIPCa and UD, respectively. pIPCa and UD were found in 15.7%, 32.1%, 25.3% (P = 0.04) and in 48.1%, 23.8%, 24.1% (P <0.001) patients with ≤12, 13-18, ≥19 cores, respectively. Among candidates for AS, number of biopsy cores emerged as an independent predictor of both pIPCa (≤12 vs 13-18: odds ratio [OR] = 2.34; P = 0.02) and UD (≤12 vs 13-18: OR = 0.39; P <0.01; ≤12 vs ≥19 cores: OR = 0.38; P <0.01).

Conclusion: Among candidates for AS, number of biopsy cores emerged as an independent predictor of pIPCa and UD at RP. These findings would suggest that the extent of initial biopsy sampling should be considered when addressing patients to AS and before planning any surveillance strategies.
Quality of life figured prominently in recommendations about therapies to use in addition to ADT, according to guideline co-chair Andrew Loblaw, MD, of Sunnybrook Odette Cancer Center in Toronto, Ontario, Canada. Patients need to understand the likely and potential side effects. Cost also will enter into discussions between clinicians and patients, because cost can affect access to treatment and quality of life.

The guidelines emphasize the situations under which specific therapies should be used (in addition to ADT):

- Abiraterone/prednisone, enzalutamide, and radium-223 should be offered to men who have disease that has spread predominately to bone; all three drugs have demonstrated improved survival, quality of life, and a favorable balance between benefits and harms.

- If chemotherapy is considered, docetaxel/prednisone should be offered and accompanied by a discussion of toxicity.

- If disease progresses on docetaxel, clinicians may offer cabazitaxel (Jevtana®), the side effects of which should also be discussed thoroughly.

- Sipuleucel-T (Provenge®) should be reserved for men with no or minimal symptoms.

- Mitoxantrone may be offered with patient understanding of the therapy’s limited clinical benefit and risk of side effects.

- Clinicians may offer ketoconazole or antiandrogens but should clearly inform patients about expectations of limited clinical benefit and a risk of side effects.

Clinicians should not give patients with mCRPC bevacizumab (Avastin®), estramustine (Emcyt®), or sunitinib (Sutent®), according to the guideline. Palliative care should be discussed with all patients early in the course of the disease, along with other treatment options. The guideline panel found evidence insufficient to recommend a specific sequence for available therapies.

The ASCO-CCO guideline follows one developed by the American Urological Association in 2013, which also emphasized appropriate use of the expanded number of treatment options for men with mCRPC but addressed sequencing, as well.

*MedPage Today, 8 September 2014*
A TREATMENT OPTION FOR ADVANCED PROSTATE CANCER THAT HAS SPREAD TO THE BONES

Prostate cancer originates in the prostate gland but may spread to other tissues. Testosterone, an androgen hormone, enhances the growth and spread of prostate cancer cells; therefore, one of the earliest types of treatment for prostate cancer is hormonal therapy that lowers testosterone levels.

Hormone therapy can help shrink or slow the growth of prostate cancer. If you are diagnosed with prostate cancer that no longer responds to medical or surgical treatments that lower testosterone, your healthcare team will conduct tests to find out whether the disease has spread beyond the prostate gland (or metastasized). Bone is the most common site of metastasis in patients with prostate cancer and bone metastases impact nearly 90% of men with CRPC.

Bone metastases can cause increased risk of death. They may be associated with symptoms, but “very few patients are able to attribute their symptoms, when they first start, to their cancer...they’re not thinking of the symptoms as cancer,” says Oliver Sartor, MD, medical director at the Tulane Cancer Center in New Orleans, LA. Your healthcare team will consider evaluating you for symptomatic bone metastases if you are experiencing weakness, problems with your posture, difficulty moving, or pain creating the need for pain medications, including those that are over-the-counter.

Be sure to talk with your healthcare team about symptoms you experience; it’s important to know that this includes any new symptoms and changes in symptoms, too.

If symptoms suggest that prostate cancer has spread to your bones, your healthcare team will talk with you about ways to treat it. Taking time to learn about your treatment options and asking questions about things that are unclear may help you to understand what to expect before, during, and after treatment. Frequent conversations with your healthcare team will help you to make more informed decisions. There are treatments available that may help slow the spread of your cancer.

Until recently, the only treatment option for metastatic CRPC that improved the chances of living longer was chemotherapy. Fortunately, in the last several years, treatment options have been approved that prolong life in patients with metastatic prostate cancer.

Different considerations come into play when deciding on a treatment, including short- and long-term side effects, the chances of living longer (with or without treatment), age, general health, and personal preferences. The healthcare team works together to create an overall treatment plan.

Creating a treatment plan involves considering the risks and benefits of available treatments. One of the available treatment options, approved May 15, 2013, is Xofigo® (radium Ra 223 dichloride) injection. Xofigo (pronounced zo-FEE-go) is a radiopharmaceutical treatment approved by the US Food and Drug Administration. It is an option for patients with prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has spread to their bones with symptoms, but not to other parts of the body.

Radium is an alkaline earth metal, discovered by Marie and Pierre Curie in 1898. Radium and calcium have similar chemical properties, so radium predominantly accumulates in areas in your bones that are growing quickly, just like calcium does. Bone metastases are one of those rapidly growing areas, which is why doctors use Xofigo to treat prostate cancer that has spread to the bones. Xofigo gives off a strong energy that helps kill cancer cells but limits damage to nearby healthy cells and tissue. Xofigo can be absorbed by organs other than the bone, primarily the bone marrow and digestive system, which can result in side effects in those healthy tissues.

Before beginning any treatment for CRPC that has spread to the bones, including Xofigo, you should talk with the healthcare team about possible side effects. In the ALSYMPCA clinical trial, 921 men with prostate cancer who had at least two bone metastases with symptoms and no known metastases were given either Xofigo or placebo by injection. In both of these groups, the men were also taking other medications for their disease.

The results of ALSYMPCA showed that the men who received Xofigo lived significantly longer; they had a median overall survival of 14.9 months vs 11.3 months in the group of placebo-treated men in an updated analysis. The survival results of ALSYMPCA were supported by a delay in their first bone-related symptom or event (called “symptomatic skeletal events”), favoring patients who were on Xofigo. Most of the events were external beam radiation therapy (treatment using a focused beam of radiation delivered from a device external to the body) to cancer spread to the bones.

Dr. Sartor notes, “I believe Xofigo is a valuable addition to the available treatment options for patients.”

Before beginning any treatment for CRPC that has spread to the bones, including Xofigo, you should talk with the healthcare team about possible side effects. Do not take Xofigo if you are pregnant or may become pregnant. Xofigo can harm your unborn baby. Women who are pregnant or who may become pregnant should not come in contact with Xofigo without protection, such as gloves. Before taking Xofigo, tell your healthcare provider if you have bone marrow problems. Xofigo can cause your blood cells counts to go down, including red blood cells, white blood cells, and/or platelets. In a clinical trial, some patients had to permanently discontinue therapy because of bone marrow problems. In addition, there were some deaths and blood transfusions that occurred due to severe bone marrow problems. Your healthcare provider will do blood tests before and during treatment with Xofigo. Also tell your healthcare provider if you are receiving any chemotherapy or another extensive radiation therapy or have any other medical conditions.

While you are on Xofigo:

Make sure you keep your blood cell count monitoring appointments and tell your healthcare provider about any symptoms or signs of low blood cell counts. Report symptoms or signs of shortness of breath, tiredness, bleeding (such as bruising), or infection (such as fever). Stay well hydrated and report any signs of dehydration (such as dry mouth and increased thirst), or urinary or kidney problems (such as burning when urinating). There are no restrictions regarding contact with other people after receiving Xofigo. Follow good hygiene practices in order to minimize radiation exposure from spills of bodily fluids to household members and caregivers for a period of one week after each injection. Use condoms and make sure female partners who may become pregnant use highly effective birth control methods during and for a minimum of six months after treatment with Xofigo. The most common side effects of Xofigo include: nausea, diarrhea, vomiting, swelling of the arms or legs (peripheral edema), and low blood cell counts.

Tell your healthcare provider if you have any side effects that bother you or do not go away.

(Continued on page 5)
A TREATMENT OPTION FOR ADVANCED PROSTATE CANCER
(Continued from page 4)

If Xofigo® (radium Ra 223 dichloride) is right for you, your healthcare provider will refer you to a clinic or facility where healthcare providers or technicians are qualified to give Xofigo. Over the course of your therapy, you will get a total of six intravenous injections of Xofigo—one injection every four weeks. The injection of Xofigo will be given over one minute.

If you have CRPC, it’s important for you—and those who care for you—to learn about your cancer care and all of your treatment options. Talk with your healthcare team about symptoms you are experiencing and your treatment plan. If you have prostate cancer that has spread to your bones, you may want to ask about Xofigo.

Xofigo is available by prescription only. To learn more about Xofigo, speak to your clinician and visit http://xofigo-us.com/patient/. Please see full Prescribing Information at http://www.xofigo-us.com/product-information/.

This article was provided to Us TOO by Bayer HealthCare. You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Bayer HealthCare

© 2014 Bayer HealthCare Pharmaceuticals. All rights reserved. BAYER, the Bayer Cross, and Xofigo are registered trademarks of Bayer. PP-600-US-0038

References


15. Provenge® (sipuleucel T) [package insert].


17. Zytiga® (abiraterone) [package insert].

18. Xtandi® (enzalutamide) [package insert].


WEAREVER INCONTINENCE BRIEFS

We’re pleased to be partnering with Wearever men’s incontinence briefs. Throughout the month of September, 10 percent of all proceeds will be donated to Us TOO.

Incontinence can be a common side effect from some prostate cancer treatments. Classic incontinence briefs and incontinence Boxer Briefs by Wearever provide another option for dealing with a little leakage. In addition to being washable and reusable, they look and feel more like regular underwear while providing a comfortable fit and absorbent protection that wicks moisture away from the body. Wearever’s incontinence briefs are constructed with sewn-in Unique-Dri™ pads and odor eliminating Agion™ antimicrobial fibers. Since each brief or boxer brief should last for 200 to 250 washes, they are more economical than disposables. Find out more at www.weareverincontinence.com.
Physician characteristics were determined from the American Medical Association Physician Masterfile. The authors developed statistical models to evaluate variation in clinical management and identify factors associated with observation. The primary outcome was absence of cancer-directed therapy during the first 12 months after diagnosis.

The analysis included 12,068 men and 2,145 urologists. Overall, 80.1% of men received upfront therapy, and 19.9% began observation. The case-adjusted rate of observation by diagnosing urologist varied almost 15-fold from the lowest (4.5%) to highest (64.2%) proportion of patients managed by observation.

Analysis of factors that affected variation in the use of observation showed that the diagnosing urologist accounted for 16.1% of the variation compared with 7.9% for patient and disease characteristics.

After adjustment for patient and tumor characteristics, the probability that a patient would be observed was 29% lower if the diagnosing urologist treated non-low-risk prostate cancer (adjusted odds ratio 0.71, 95% CI 0.55-0.92, P<0.001).

Men who saw only a urologist were significantly more likely to be observed than were men who were seen by a urologist and a radiation oncologist (43.8% versus 8.6%, P<0.001). Authors found that 70.8% of men observed saw only a urologist. Men older than age 70 and with clinical T2 disease at diagnosis were significantly more likely to be observed (P<0.001). However, 55.1% of men older than 80 underwent upfront definitive treatment. Comorbidity score and PSA level did not significantly affect the likelihood of observation.

“We weren’t necessarily surprised by the findings, but the extent of variation in management of low-risk prostate cancer across physicians was quite striking,” Hoffman told MedPage Today.

“The evidence of substantial variation in the approach to treatment means that patients with low-risk prostate cancer should take the initiative to ask whether they are candidates for observation,” she added. Public reporting of the data will allow primary care physicians to seek out urologists who are inclined to recommend observation for low-risk cases.

---

**Physician characteristics were determined from the American Medical Association Physician Masterfile. The authors developed statistical models to evaluate variation in clinical management and identify factors associated with observation. The primary outcome was absence of cancer-directed therapy during the first 12 months after diagnosis. The analysis included 12,068 men and 2,145 urologists. Overall, 80.1% of men received upfront therapy, and 19.9% began observation. The case-adjusted rate of observation by diagnosing urologist varied almost 15-fold from the lowest (4.5%) to highest (64.2%) proportion of patients managed by observation. Analysis of factors that affected variation in the use of observation showed that the diagnosing urologist accounted for 16.1% of the variation compared with 7.9% for patient and disease characteristics. After adjustment for patient and tumor characteristics, the probability that a patient would be observed was 29% lower if the diagnosing urologist treated non-low-risk prostate cancer (adjusted odds ratio 0.71, 95% CI 0.55-0.92, P<0.001). Men who saw only a urologist were significantly more likely to be observed than were men who were seen by a urologist and a radiation oncologist (43.8% versus 8.6%, P<0.001). Authors found that 70.8% of men observed saw only a urologist. Men older than age 70 and with clinical T2 disease at diagnosis were significantly more likely to be observed (P<0.001). However, 55.1% of men older than 80 underwent upfront definitive treatment. Comorbidity score and PSA level did not significantly affect the likelihood of observation. “We weren’t necessarily surprised by the findings, but the extent of variation in management of low-risk prostate cancer across physicians was quite striking,” Hoffman told MedPage Today. “The evidence of substantial variation in the approach to treatment means that patients with low-risk prostate cancer should take the initiative to ask whether they are candidates for observation,” she added. Public reporting of the data will allow primary care physicians to seek out urologists who are inclined to recommend observation for low-risk cases.**

---

**Physician characteristics were determined from the American Medical Association Physician Masterfile. The authors developed statistical models to evaluate variation in clinical management and identify factors associated with observation. The primary outcome was absence of cancer-directed therapy during the first 12 months after diagnosis. The analysis included 12,068 men and 2,145 urologists. Overall, 80.1% of men received upfront therapy, and 19.9% began observation. The case-adjusted rate of observation by diagnosing urologist varied almost 15-fold from the lowest (4.5%) to highest (64.2%) proportion of patients managed by observation. Analysis of factors that affected variation in the use of observation showed that the diagnosing urologist accounted for 16.1% of the variation compared with 7.9% for patient and disease characteristics. After adjustment for patient and tumor characteristics, the probability that a patient would be observed was 29% lower if the diagnosing urologist treated non-low-risk prostate cancer (adjusted odds ratio 0.71, 95% CI 0.55-0.92, P<0.001). Men who saw only a urologist were significantly more likely to be observed than were men who were seen by a urologist and a radiation oncologist (43.8% versus 8.6%, P<0.001). Authors found that 70.8% of men observed saw only a urologist. Men older than age 70 and with clinical T2 disease at diagnosis were significantly more likely to be observed (P<0.001). However, 55.1% of men older than 80 underwent upfront definitive treatment. Comorbidity score and PSA level did not significantly affect the likelihood of observation. “We weren’t necessarily surprised by the findings, but the extent of variation in management of low-risk prostate cancer across physicians was quite striking,” Hoffman told MedPage Today. “The evidence of substantial variation in the approach to treatment means that patients with low-risk prostate cancer should take the initiative to ask whether they are candidates for observation,” she added. Public reporting of the data will allow primary care physicians to seek out urologists who are inclined to recommend observation for low-risk cases.**
a1p1c1 As interest in active surveillance grows, newly diagnosed men should realize that their likelihood of having this treatment is dependent on factors beyond the characteristics of their tumor. The study by Hoffman and co-workers found that patients were significantly more likely to undergo local therapy if their doctor was a D.O., were trained in certain time periods, or they saw both a urologist and a radiation therapist compared to a urologist alone. The treatment also was influenced by the treatments offered; patients whose doctor performed cryosurgery or brachytherapy were more likely to have one of those treatments than when their doctor did not perform them. Surprisingly, 55% of men over the age of 80 had local therapy. This should come as no surprise because presently doctors make their own decision regarding the information given to patients about treatment options. Unless or until some standardized information is made available to all patients, the biases of their doctor will greatly influence which treatment they receive. That places an added burden on all men and their families to carefully investigate the pros and cons of the various options.

The Bottom Line: As I have previously written in this column, men should specifically ask about the odds of the treatments helping them live longer or improving their quality of life compared to active surveillance. One critique of this paper is that it only includes men treated up to 2009 and results may have changed significantly during the last five years.

a4p2c2 Choline PET scans are increasingly being used in the management of men with prostate cancer, although its true value still remains uncertain. One of the challenges is variability in the interpretation of the scans. In an effort to define this variability, Pegard, et al evaluated the results for four doctors evaluating scans in patients who had a biochemical recurrence following local therapy. They used the Fleiss' kappa coefficient to assess the variability between these doctors. This value ranges from 0 to 1, where 0 means there is no consistency and 1 means there is complete agreement. No one has determined what an acceptable value is. Here the authors report a Fleiss' kappa coefficient of 0.55, which seems like it is only a fair result. They found the weakest correlation in men with an intact prostate. Although the agreement was better for lymph node involvement, one might reasonably ask, “So what?” The only purpose for considering this test after radical prostatectomy is to determine if salvage radiation is worth doing and studies have shown limited benefit. Knowing that a patient has recurrence in the lymph nodes does little to help guide therapy because there is no known survival benefit from early ADT in these men. Another concern with the findings is the authors did not show how the PSA level might impact on the findings.

The Bottom Line: It would have been helpful to know the level of agreement at different PSA levels. Perhaps concordance is not very good unless the PSA is above a certain value. Nevertheless, this is a first attempt to demonstrate variability in interpreting PET scans and more work in this area is needed.

a5p2c3 One of the challenges facing men considering active surveillance is whether the prostate biopsy has adequately sampled the gland. In the United States, a 12-core biopsy has become the standard, but many doctors still do more than that number. Also, some doctors advise a repeat biopsy before advising active surveillance. A question that has not been resolved is whether doing more than 12 cores at the initial biopsy would enable men to avoid having to undergo a second biopsy. This has been partly addressed by Villa et al who correlated the number of biopsies with the findings at radical prostatectomy. Although they did find some correlation, a weakness of the paper is they combined all Gleason 7 cancers together, i.e., 3+4=7 and 4+3=7. The problem with this approach is many men with Gleason 3+4=7 are still considered candidates for active surveillance.

The Bottom Line: To really determine if patients would be better served by having more than a 12-core biopsy, the data would need to be re-analyzed by separating the patients with Gleason 7 tumors into the two groups.

a8p6c3 The article by Daskivitch et al provides further support for the over-treatment of men with low- or intermediate-risk disease. They looked at SEER data from 1991-2007 and correlated the likelihood of men over 65 getting treated based on their life expectancy. Obviously, doctors cannot predict with certainty the time when someone will die. All that can be done is to talk about percentages of men surviving for a defined number of years based on age and overall health. When choosing therapy, many patients expect their survival to be longer than what will actually occur. That might help explain why the authors found a significant percentage of men with life expectancies less than 10 years get local therapy. That means a large percentage of them are getting treated with almost no chance of benefitting.

The Bottom Line: Something seems wrong when 68% of all men with a life expectancy less than 10 years or 24% of men over 80 years of age are getting surgery, radiation, or brachytherapy. The message to patients is to ask your family doctor to give you some idea about your life expectancy based on your age and health status so you are in a better position to decide if the possible benefits of treatment really do outweigh the risks.

a1op8c1 As has been discussed in the past, significant progress has been made in managing castrate-resistant prostate cancer. In addition to sipuleucel-T (Provenge®), abiraterone acetate (Zytiga®), and radium Ra-223 dichloride (Xofigo®) being approved prior to docetaxel chemotherapy, the FDA just announced approval of enzalutamide (Xtandi®) for those same patients. All these agents improve survival. For those failing docetaxel/prednisone, cabazitaxel is also approved. Now comes the hard part; figuring out the best sequence, which is likely to vary among patients.

The Bottom Line: Until definitive studies are done, doctors are likely to have a variable approach. Cost and side effects are two factors that need to be considered. One question is whether administering sipuleucel-T is the best place to start in men with minimal or no symptoms and then proceeding on to either abiraterone/prednisone or enzalutamide. For those who do have significant bone pain, radium Ra-223 dichloride rather than sipuleucel-T seems most reasonable. Hopefully, definitive studies will be published soon to help patients and doctors make treatment decisions.
Medivation, Inc. and Astellas Pharma Inc. announced that the US Food and Drug Administration (FDA) approved a new indication for the use of XTANDI® (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). This new approved use follows a priority review of the supplemental New Drug Application (sNDA) that was based on results of the Phase 3 PREVAIL trial.

The FDA initially approved XTANDI, an oral, once-daily androgen receptor inhibitor, in August 2012 for use in patients with metastatic CRPC who previously received docetaxel (chemotherapy). The new indication approves XTANDI for use in men with metastatic CRPC who have not received chemotherapy. Metastatic CRPC is defined as a cancer that has spread beyond the prostate gland and has progressed despite treatment to lower testosterone (i.e., with a gonadotropin-releasing hormone (GnRH) therapy or with removal of the testes). Enzalutamide is an androgen receptor inhibitor that acts on three different steps in the androgen receptor signaling pathway.

In the Phase 3 PREVAIL trial, men receiving XTANDI and GnRH therapy exhibited a statistically significant improvement in both overall survival and delayed time to radiographic progression or death as compared to those on placebo and GnRH therapy.

XTANDI significantly reduced the risk of radiographic progression or death by 83% compared with placebo (HR=0.17; p <0.0001). XTANDI significantly reduced the risk of death by 29% compared with placebo (HR=0.71; p <0.0001). When compared to placebo, treatment with XTANDI also delayed time to initiation of chemotherapy and time to a skeletal-related event.

The safety profile for XTANDI was updated to reflect data from both the AFFIRM and PREVAIL Phase 3 trials. Seizure occurred in 0.9% of patients receiving XTANDI who previously received docetaxel and 0.1% of patients who were chemotherapy-naïve. The most common adverse reactions (≥10%) that occurred more commonly (≥2% over placebo) in the XTANDI-treated patients from the two randomized clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspea, musculoskeletal pain, weight decreased, headache, hypotension, and dizziness/vertigo.

“All of us at Medivation extend our thanks to the clinicians and patients who participated in the PREVAIL clinical trial culminating in today’s approval,” said David Hung, MD, founder, president and chief executive officer, Medivation, Inc. “As a company dedicated to the rapid development of novel therapies to treat serious diseases, we are pleased to see XTANDI approved in this important patient population.”

MarketWire, 10 September 2014

CHOLINE PET/CT
(Continued from page 2)

interpretation of (18F) choline positron emission tomography/computed tomography examinations, which is a key examination for the treatment of patients suffering biochemical recurrence of prostate cancer. Interpretation of the (18F) choline emission tomography/computed tomography examination is not so useful at prostate level in patients not previously treated with prostatectomy but has a great interest on patients treated by prostatectomy. It showed good concordance in the interpretation of sub-diaphragmatic lymphatic recurrences as well as in bone metastasis.

HotSheet Personal Subscriptions Available

We can deliver the HotSheet newsletter right to your home or office. Support the creation and distribution of the HotSheet with a suggested annual subscription donation of $35 for 12 issues (includes shipping and handling). To obtain an order form or to order online, go to: www.ustoo.org/Hot_Sheets.asp, or call 1-800-808-7866 (1-800-80-UsTOO).

Us TOO INTERNATIONAL:
Our Mission
Be the leading prostate cancer organization helping men and their families make informed decisions about prostate cancer detection, treatment and side effects through support, education and advocacy.

Us TOO INTERNATIONAL Tax Deductible Donation

Name: ___________________________ Company: ___________________________

Address: ___________________________ Suite/Unit #:________

City: ___________________________ State: _____ ZIP: ________ Country: ________

Phone: (____) ________ Fax: (____) ________ Email: __________________________

Please accept my enclosed tax-deductible donation to Us TOO International, a non-profit 501(c)(3) organization.

Amount: $50 $75 $100 $200 Other: $ ________ Check # __________

VISA/MC/AMEX/DISC # ___________________________ Expiration Date: _____ /_____ CVV#: _______

Signature ___________________________ Date: __________

☐ Check here if you wish to remain anonymous Annual Report donor recognition listing

Us TOO INTERNATIONAL, 2720 S. River Road, Suite 112, Des Plaines, IL 60018